MiMedx Group Inc. (MDXG) Performance and Fundamentals Dashboard tells a completely different story

MiMedx Group Inc. (NASDAQ: MDXG) stock jumped 0.40% on Monday to $7.57 against a previous-day closing price of $7.54. With 0.5 million shares changed hands, the volume of the stock remained lighter than its average volume of 0.84 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $7.58 whereas the lowest price it dropped to was $7.39. The 52-week range on MDXG shows that it touched its highest point at $8.60 and its lowest point at $2.43 during that stretch. It currently has a 1-year price target of $12.06. Beta for the stock currently stands at 1.61.

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of MDXG was down-trending over the past week, with a drop of -7.23%, but this was up by 3.56% over a month. Three-month performance surged to 32.11% while six-month performance rose 105.15%. The stock gained 120.06% in the past year, while it has gained 172.30% so far this year. A look at the trailing 12-month EPS for MDXG yields -0.17 with Next year EPS estimates of 0.30. For the next quarter, that number is 0.04. This implies an EPS growth rate of -118.90% for this year and 332.86% for next year. EPS is expected to grow by 15.00% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -22.10%.

Float and Shares Shorts:

At present, 115.87 million MDXG shares are outstanding with a float of 110.45 million shares on hand for trading. On Aug 30, 2023, short shares totaled 3.26 million, which was 2.80% higher than short shares on Jul 30, 2023. In addition to Mr. William F. Hulse IV as the firm’s Gen. Counsel & Chief Admin. Officer, Dr. Robert Benjamin Stein M.D., Ph.D. serves as its Pres of Regenerative Medicine & Biologics Innovation.

Institutional Ownership:

Through their ownership of 66.97% of MDXG’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 31.42% of MDXG, in contrast to 28.33% held by mutual funds. Shares owned by individuals account for 19.13%. As the largest shareholder in MDXG with 6.55% of the stake, Prescience Investment Group LLC holds 7,602,577 shares worth 7,602,577. A second-largest stockholder of MDXG, BlackRock Fund Advisors, holds 7,197,496 shares, controlling over 6.20% of the firm’s shares. The Vanguard Group, Inc. is the third largest shareholder in MDXG, holding 6,021,734 shares or 5.19% stake. With a 2.90% stake in MDXG, the Vanguard Total Stock Market ETF is the largest stakeholder. A total of 3,362,582 shares are owned by the mutual fund manager. The iShares Russell 2000 ETF, which owns about 2.20% of MDXG stock, is the second-largest Mutual Fund holder. It holds 2,551,476 shares valued at 18.93 million. Vanguard Extended Market Index Fu holds 1.40% of the stake in MDXG, owning 1,622,005 shares worth 12.04 million.

An Overview of Recent Financials:

Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on Jun 29, 2023, MDXG reported revenue of $66.88M and operating income of -$9.64M. The EBITDA in the recently reported quarter was -$8.61M and diluted EPS was -$0.11.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for MDXG since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With MDXG analysts setting a high price target of $14.00 and a low target of $11.00, the average target price over the next 12 months is $12.06. Based on these targets, MDXG could surge 84.94% to reach the target high and rise by 45.31% to reach the target low. Reaching the average price target will result in a growth of 59.31% from current levels.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy.

Summary of Insider Activity:

Insiders traded MDXG stock several times over the past three months with 3 Buys and 0 Sells. In these transactions, 197,200 shares were bought while 0 shares were sold. The number of buy transactions has increased to 15 while that of sell transactions has risen to 23 over the past year. The total number of shares bought during that period was 1,372,449 while 208,320 shares were sold.

Leave a Comment

Your email address will not be published. Required fields are marked *